These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 15864114)

  • 1. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
    García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
    Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
    Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
    Santos PC; Morgan AC; Jannes CE; Turolla L; Krieger JE; Santos RD; Pereira AC
    Atherosclerosis; 2014 Mar; 233(1):206-10. PubMed ID: 24529145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia.
    Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D
    Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
    Vuorio AF; Ojala JP; Sarna S; Turtola H; Tikkanen MJ; Kontula K
    J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry.
    Roy G; Couture P; Genest J; Ruel I; Baass A; Bergeron J; Brisson D; Brunham LR; Cermakova L; Gaudet D; Khoury E; Laflamme N; Kennedy BA; Hegele RA; Drouin-Chartier JP
    Can J Cardiol; 2022 Mar; 38(3):311-319. PubMed ID: 34774719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
    Nozue T; Michishita I; Ito Y; Hirano T
    J Atheroscler Thromb; 2008 Jun; 15(3):146-53. PubMed ID: 18603821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population.
    Ejarque I; Real JT; Martinez-Hervas S; Chaves FJ; Blesa S; Garcia-Garcia AB; Millan E; Ascaso JF; Carmena R
    Transl Res; 2008 Mar; 151(3):162-7. PubMed ID: 18279815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
    Larivière M; Lamarche B; Pirro M; Hogue JC; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2003 Mar; 167(1):97-104. PubMed ID: 12618273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
    Telford DE; Edwards JY; Lipson SM; Sutherland B; Barrett PH; Burnett JR; Krul ES; Keller BT; Huff MW
    J Lipid Res; 2003 May; 44(5):943-52. PubMed ID: 12562847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations.
    Tichý L; Freiberger T; Zapletalová P; Soška V; Ravčuková B; Fajkusová L
    Atherosclerosis; 2012 Aug; 223(2):401-8. PubMed ID: 22698793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Futema M; Ramaswami U; Tichy L; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; De Leener A; Fastre E; Vrablik M; Freiberger T; Esterbauer H; Dieplinger H; Greber-Platzer S; Medeiros AM; Bourbon M; Mollaki V; Drogari E; Humphries SE
    Atherosclerosis; 2021 Feb; 319():108-117. PubMed ID: 33508743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.